• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Extrafine particles and the potential for enhanced inhaled drug delivery: A Q&A with Chiesi’s Dave Lewis

Dave Lewis

Dave Lewis is Head of Laboratory at Chiesi

Q: What benefits are offered by extrafine particles?
A:
 There is growing evidence to suggest that finer aerosols may enable us to effectively direct particles into more efficacious areas of the lung and to achieve a more uniform localized response. Furthermore, data we presented at RDD 2016 demonstrate that finer particles could deliver performance that is more independent of the flow rate applied during use, which would reduce the variability associated with different patient groups.

Better performance in either of these areas could deliver substantial gains in clinical efficacy.

Q: Why do you think that extrafine particles would deposit more efficaciously?
A:
 Since I began my career in this field, around 20 years ago, the main drivers for improvement have been 1) advances in device design, 2) better characterization and knowledge of drug formulations, and 3) an enhanced understanding of human physiology.

Improvements in analytical capabilities across the board have made it easier to understand the interplay between device, formulation, and patient, and how to control performance to meet our aims. We continue to refine our understanding of how to improve upon what are, in general, relatively low levels of drug delivery efficiency.

Understanding where the formulation needs to be deposited in the lung for greatest efficacy, and the particle size needed to achieve this deposition, has always been crucial. Historically we’ve focused on the behavior of particles within the 1-5 µm range, on the premise that particles need to be less than 5 µm to reach the lung, but particles of less than 1 µm tend to be exhaled.

Recent studies suggest that it may be time to re-examine this premise and look more closely at particles towards the lower end of this range, and indeed finer. A review by Usmani, for example, highlighted that persistent small airway dysfunction is a recognized trait in certain asthma sufferers. These studies showed that extrafine particles could, in fact, penetrate deep into the lung thereby “unlocking the small airways compartment.”

Share
1 2 3 4 5 6Next page »

published on January 31, 2017

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Aptar Pharma banner
    © 2025 OINDPnews